Vitamin D3 supplementation in adults with bronchiectasis: A pilot study

被引:19
作者
Bartley, Jim [1 ]
Garrett, Jeff [2 ]
Camargo, Carlos A., Jr. [3 ]
Scragg, Robert [4 ]
Vandal, Alain [5 ,6 ]
Sisk, Rose [5 ]
Milne, David [7 ]
Tai, Ray [7 ]
Jeon, Gene [8 ]
Cursons, Ray [9 ]
Wong, Conroy [2 ]
机构
[1] Univ Auckland, Dept Surg, 10 Owens Rd, Auckland 1023, New Zealand
[2] Middlemore Hosp, Dept Resp Med, Auckland, New Zealand
[3] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA
[4] Univ Auckland, Sch Populat Hlth, Auckland, New Zealand
[5] Auckland Univ Technol, Fac Hlth & Environm Sci, Dept Biostat & Epidemiol, Auckland, New Zealand
[6] Ko Awatea, Counties Manukau Dist Hlth Board, Auckland, New Zealand
[7] Auckland City Hosp, Dept Radiol, Auckland Dist Hlth Board, Auckland, New Zealand
[8] Middlemore Hosp, Middlemore Clin Trials Unit, Auckland, New Zealand
[9] Univ Waikato, Fac Sci & Engn, Hamilton, New Zealand
关键词
Bronchiectasis; chronic rhinosinusitis; Dartmouth COOP charts; quality of life; Leicester Cough Questionnaire; vitamin D; QUALITY-OF-LIFE; CYSTIC FIBROSIS BRONCHIECTASIS; SERUM 25-HYDROXYVITAMIN D; 3RD NATIONAL-HEALTH; DOUBLE-BLIND; LONG-TERM; EXACERBATIONS; DISEASE; RHINOSINUSITIS; AZITHROMYCIN;
D O I
10.1177/1479972318761646
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Vitamin D supplementation prevents acute respiratory infections and, through modulating innate and adaptive immunity, could have a potential role in bronchiectasis management. The primary aims of this pilot study were to assess serum 25-hydroxyvitamin D (25(OH)D) levels in New Zealand adults with bronchiectasis, and their 25(OH)D levels after vitamin D-3 supplementation. Adults with bronchiectasis received an initial 2.5 mg vitamin D-3 oral loading dose and 0.625 mg vitamin D-3 weekly for 24 weeks. The primary outcome was serum 25(OH)D levels before and after vitamin D-3 supplementation. Secondary outcomes (time to first infective exacerbation, exacerbation frequency, spirometry, health-related quality of life measures, sputum bacteriology and cell counts and chronic rhinosinusitis) were also assessed. This study is registered with the Australian New Zealand Clinical Trials Registry (ACTRN 12612001222831). The initial, average 25(OH)D level was 71 nmol/L (95% confidence interval (CI): [58, 84]), rising to 218 nmol/L (95% CI: [199, 237]) at 12 weeks and 205 nmol/L (95% CI: [186, 224]) at 24 weeks. The initial serum cathelicidin level was 25 nmol/L (95% CI: [17, 33]), rising to 102 nmol/L (95% CI: [48, 156]) at 12 weeks and 151 nmol/L (95% CI: [97, 205]) at 24 weeks. Over the 24-week study period, we observed statistically significant changes of 1.11 (95% CI: [0.08, 2.14]) in the Leicester Cough Questionnaire and -1.97 (95% CI: [-3.71, -0.23]) in the Dartmouth COOP charts score. No significant adverse effects were recorded. Many New Zealand adults with bronchiectasis have adequate 25(OH)D levels. Weekly vitamin D-3 supplementation significantly improved 25(OH)D levels.
引用
收藏
页码:384 / 392
页数:9
相关论文
共 42 条
[31]   Serum 25-hydroxyvitamin D concentrations of New Zealanders aged 15 years and older [J].
Rockell, J. E. P. ;
Skeaff, C. M. ;
Williams, S. M. ;
Green, T. J. .
OSTEOPOROSIS INTERNATIONAL, 2006, 17 (09) :1382-1389
[32]   Serum 25-Hydroxyvitamin D and the Incidence of Acute Viral Respiratory Tract Infections in Healthy Adults [J].
Sabetta, James R. ;
DePetrillo, Paolo ;
Cipriani, Ralph J. ;
Smardin, Joanne ;
Burns, Lillian A. ;
Landry, Marie L. .
PLOS ONE, 2010, 5 (06)
[33]   Effect of Long-term, Low-Dose Erythromycin on Pulmonary Exacerbations Among Patients With Non-Cystic Fibrosis Bronchiectasis The BLESS Randomized Controlled Trial [J].
Serisier, David J. ;
Martin, Megan L. ;
McGuckin, Michael A. ;
Lourie, Rohan ;
Chen, Alice C. ;
Brain, Barbara ;
Biga, Sally ;
Schlebusch, Sanmarie ;
Dash, Peter ;
Bowler, Simon D. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 309 (12) :1260-1267
[34]   Is hypovitaminosis D a consequence rather than cause of disease? [J].
Shee, Charles .
THORAX, 2013, 68 (07) :679-679
[35]   The validity of health-related quality of life questionnaires in bronchiectasis: a systematic review and meta-analysis [J].
Spinou, Arietta ;
Fragkos, Konstantinos C. ;
Lee, Kai K. ;
Elston, Caroline ;
Siegert, Richard J. ;
Loebinger, Michael R. ;
Wilson, Robert ;
Garrod, Rachel ;
Birring, Surinder S. .
THORAX, 2016, 71 (08) :683-694
[36]   The relationship between serum vitamin D and chronic rhinosinusitis: A systematic review [J].
Stokes, Patrick J. ;
Rimmer, Joanne .
AMERICAN JOURNAL OF RHINOLOGY & ALLERGY, 2016, 30 (01) :23-28
[37]   Nasal Levels of Antimicrobial Peptides in Allergic Asthma Patients and Healthy Controls: Differences and Effect of a Short 1,25(OH)2 Vitamin D3 Treatment [J].
Thijs, Willemien ;
Janssen, Kirsten ;
van Schadewijk, Annemarie M. ;
Papapoulos, Socrates E. ;
le Cessie, Saskia ;
Middeldorp, Saskia ;
Melissant, Christian F. ;
Rabe, Klaus F. ;
Hiemstra, Pieter S. .
PLoS One, 2015, 10 (11)
[38]  
Vieth R, 2009, ANTICANCER RES, V29, P3675
[39]   Interventions for bronchiectasis: an overview of Cochrane systematic reviews [J].
Welsh, Emma J. ;
Evans, David J. ;
Fowler, Stephen J. ;
Spencer, Sally .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (07)
[40]   Moderate Amounts of Vitamin D3 in Supplements are Effective in Raising Serum 25-Hydroxyvitamin D from Low Baseline Levels in Adults: A Systematic Review [J].
Whiting, Susan J. ;
Bonjour, Jean-Philippe ;
Payen, Flore Dontot ;
Rousseau, Brigitte .
NUTRIENTS, 2015, 7 (04) :2311-2323